Theratechnologies (TSE:TH) Reaches New 52-Week High - Still a Buy?

Key Points

• Theratechnologies Inc. reached a new 1-year high of C$4.49 during mid-day trading, reflecting a significant milestone for the company.
• Despite the recent highs, Wall Street analysts have downgraded Theratechnologies from a "strong-buy" to a "hold" rating.
• The company specializes in addressing unmet medical needs for HIV patients and has a market cap of C$143.26 million, alongside a high beta of 1.73, indicating potential volatility.

Theratechnologies Inc. (TSE:TH - Get Free Report)'s share price hit a new 52-week high on Monday . The company traded as high as C$4.49 and last traded at C$4.48, with a volume of 2116 shares changing hands. The stock had previously closed at C$4.48.

Analyst Upgrades and Downgrades

Separately, Jones Trading lowered shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 3rd. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy".

Theratechnologies Stock Down 0.4%

The company has a market capitalization of C$143.89 million, a price-to-earnings ratio of -51.05, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73. The firm's 50 day moving average price is C$4.07 and its two-hundred day moving average price is C$3.33. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of -293.92.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.